menu
    • menu
    [{"orgOrder":0,"company":"Radiation Therapy Oncology Group","sponsor":"National Cancer Institute | NRG Oncology","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Pharmacology\/Toxicology","graph2":"Phase II","graph3":"Radiation Therapy Oncology Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Radiation Therapy Oncology Group \/ National Cancer Institute | NRG Oncology","highestDevelopmentStatusID":"8","companyTruncated":"Radiation Therapy Oncology Group \/ National Cancer Institute | NRG Oncology"},{"orgOrder":0,"company":"Anebulo Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Selonabant","moa":"CNR1","graph1":"Pharmacology\/Toxicology","graph2":"Phase II","graph3":"Anebulo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Anebulo Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Anebulo Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Anebulo Pharmaceuticals","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Pharmacology\/Toxicology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Funding","leadProduct":"Selonabant","moa":"CNR1","graph1":"Pharmacology\/Toxicology","graph2":"Phase II","graph3":"Anebulo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Anebulo Pharmaceuticals \/ National Institutes of Health","highestDevelopmentStatusID":"8","companyTruncated":"Anebulo Pharmaceuticals \/ National Institutes of Health"},{"orgOrder":0,"company":"Chr. Hansen","sponsor":"Atlantia Food Clinical Trials","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"DENMARK","productType":"Probiotic","year":"2017","type":"Inapplicable","leadProduct":"Probiotic","moa":"Immune","graph1":"Pharmacology\/Toxicology","graph2":"Phase II","graph3":"Chr. Hansen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chr. Hansen \/ Atlantia Food Clinical Trials","highestDevelopmentStatusID":"8","companyTruncated":"Chr. Hansen \/ Atlantia Food Clinical Trials"},{"orgOrder":0,"company":"EmeraMed","sponsor":"NBMI Science AB","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"IRELAND","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Emeramide","moa":"Mercury | Iron","graph1":"Pharmacology\/Toxicology","graph2":"Phase II","graph3":"EmeraMed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"EmeraMed \/ NBMI Science AB","highestDevelopmentStatusID":"8","companyTruncated":"EmeraMed \/ NBMI Science AB"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Itacitinib","moa":"Tyrosine-protein kinase JAK1","graph1":"Pharmacology\/Toxicology","graph2":"Phase II","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Incyte Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Incyte Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Jianersheng Pharmaceutical Technology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"CHINA","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"GMDTC","moa":"Undisclosed","graph1":"Pharmacology\/Toxicology","graph2":"Phase II","graph3":"Jianersheng Pharmaceutical Technology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Jianersheng Pharmaceutical Technology \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Jianersheng Pharmaceutical Technology \/ Undisclosed"},{"orgOrder":0,"company":"Jianersheng Pharmaceutical Technology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"CHINA","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"GMDTC","moa":"Undisclosed","graph1":"Pharmacology\/Toxicology","graph2":"Phase II","graph3":"Jianersheng Pharmaceutical Technology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Jianersheng Pharmaceutical Technology \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Jianersheng Pharmaceutical Technology \/ Undisclosed"},{"orgOrder":0,"company":"Jianersheng Pharmaceutical Technology","sponsor":"Guangdong Provincial Hospital for Occupational Disease Prevention and Treatment","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"CHINA","productType":"Antibiotic","year":"2025","type":"Inapplicable","leadProduct":"GMDTC","moa":"Undisclosed","graph1":"Pharmacology\/Toxicology","graph2":"Phase II","graph3":"Jianersheng Pharmaceutical Technology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Jianersheng Pharmaceutical Technology \/ Guangdong Provincial Hospital for Occupational Disease Prevention and Treatment","highestDevelopmentStatusID":"8","companyTruncated":"Jianersheng Pharmaceutical Technology \/ Guangdong Provincial Hospital for Occupational Disease Prevention and Treatment"},{"orgOrder":0,"company":"CSPC Ouyi Pharmaceutical Co., Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"SYHX1901","moa":"Undisclosed","graph1":"Pharmacology\/Toxicology","graph2":"Phase II","graph3":"CSPC Ouyi Pharmaceutical Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CSPC Ouyi Pharmaceutical Co., Ltd \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"CSPC Ouyi Pharmaceutical Co., Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Prisma Health-Upstate","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Therapeutic Plasma Exchange","moa":"Undisclosed","graph1":"Pharmacology\/Toxicology","graph2":"Phase II","graph3":"Prisma Health-Upstate","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Prisma Health-Upstate \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Prisma Health-Upstate \/ Undisclosed"},{"orgOrder":0,"company":"Groupe Persavita","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"CANADA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Pharmacology\/Toxicology","graph2":"Phase II","graph3":"Groupe Persavita","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Groupe Persavita \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Groupe Persavita \/ Undisclosed"}]

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Jianersheng Pharmaceutical Technology

                            Country arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Jianersheng Pharmaceutical Technology

                            Country arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : GMDTC

                            Therapeutic Area : Pharmacology/Toxicology

                            Study Phase : Phase II

                            Sponsor : Guangdong Provincial Hospital for Occupational Disease Prevention and Treatment

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            The Safety and Efficacy of GMDTC for Injection in Subjects with Elevated Cadmium Levels

                            Details : GMDTC is a Antibiotic drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Cadmium Poisoning.

                            Product Name : Undisclosed

                            Product Type : Antibiotic

                            Upfront Cash : Inapplicable

                            July 09, 2025

                            Lead Product(s) : GMDTC

                            Therapeutic Area : Pharmacology/Toxicology

                            Highest Development Status : Phase II

                            Sponsor : Guangdong Provincial Hospital for Occupational Disease Prevention and Treatment

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Anebulo Pharmaceuticals

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Anebulo Pharmaceuticals

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Selonabant

                            Therapeutic Area : Pharmacology/Toxicology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Anebulo Pharmaceuticals Announces Positive Regulatory Update for Selonabant

                            Details : ANEB-001 (selonabant) is a CB1 receptor inhibitor, being evaluated for the potential use as an emergency treatment of acute cannabis-induced toxicities, including cannabis-induced CNS depression.

                            Product Name : Undisclosed

                            Product Type : Controlled Substance

                            Upfront Cash : Inapplicable

                            December 23, 2024

                            Lead Product(s) : Selonabant

                            Therapeutic Area : Pharmacology/Toxicology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Anebulo Pharmaceuticals

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Anebulo Pharmaceuticals

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Selonabant

                            Therapeutic Area : Pharmacology/Toxicology

                            Study Phase : Phase II

                            Sponsor : National Institutes of Health

                            Deal Size : $1.9 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            Anebulo Pharmaceuticals Awarded NIDA Grant for Acute Cannabis-Induced Toxic Effects

                            Details : The funding aims to support the development of ANEB-001 (selonabant) for the potential use as an emergency treatment of acute cannabis-induced toxicities, including cannabis-induced CNS depression.

                            Product Name : Undisclosed

                            Product Type : Controlled Substance

                            Upfront Cash : Undisclosed

                            July 22, 2024

                            Lead Product(s) : Selonabant

                            Therapeutic Area : Pharmacology/Toxicology

                            Highest Development Status : Phase II

                            Sponsor : National Institutes of Health

                            Deal Size : $1.9 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Crinetics Pharmaceuticals

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Crinetics Pharmaceuticals

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Paltusotine

                            Therapeutic Area : Pharmacology/Toxicology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Crinetics Reports Positive Topline Data from Phase 2 of Paltusotine for Carcinoid Syndrome

                            Details : Crinetics lead product candidate CRN00808 (paltusotine), an SST2 agonist. Currently, it is being evaluated in the Phase II clinical trial studies for the treatment of Carcinoid Syndrome.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 12, 2024

                            Lead Product(s) : Paltusotine

                            Therapeutic Area : Pharmacology/Toxicology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            CSPC Ouyi Pharmaceutical Co., Ltd

                            China arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            CSPC Ouyi Pharmaceutical Co., Ltd

                            China arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SYHX1901

                            Therapeutic Area : Pharmacology/Toxicology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            An Investigational Study to Evaluate Experimental Medication SYHX1901 Tablets With Moderate to Severe Plaque P...

                            Details : SYHX1901 is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Drug-Related Side Effects and Adverse Reactions.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            May 15, 2023

                            Lead Product(s) : SYHX1901

                            Therapeutic Area : Pharmacology/Toxicology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Groupe Persavita

                            Canada arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Groupe Persavita

                            Canada arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Pharmacology/Toxicology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Persavita is Preparing for a Clinical Trial to Test its Experimental Natural Health Product in Covid-19

                            Details : Persavita's experimental product is composed of three natural ingredients with known immune modulating properties. The company is gearing up to test this experimental product in Covid-19 patients through a phase 2 clinical study already authorized by Hea...

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            November 20, 2020

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Pharmacology/Toxicology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Prisma Health-Upstate

                            Country arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Prisma Health-Upstate

                            Country arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Therapeutic Plasma Exchange

                            Therapeutic Area : Pharmacology/Toxicology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Therapeutic Plasma Exchange Alone or in Combination With Ruxolitinib in COVID-19 Associated CRS

                            Details : Therapeutic Plasma Exchange is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Cytokine Release Syndrome.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            May 05, 2020

                            Lead Product(s) : Therapeutic Plasma Exchange

                            Therapeutic Area : Pharmacology/Toxicology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Incyte Corporation

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Incyte Corporation

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Itacitinib

                            Therapeutic Area : Pharmacology/Toxicology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study of Itacitinib for the Prevention of Cytokine Release Syndrome Induced by Immune Effector Cell Therapy

                            Details : Itacitinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Cytokine Release Syndrome.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            August 28, 2019

                            Lead Product(s) : Itacitinib

                            Therapeutic Area : Pharmacology/Toxicology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Chr. Hansen

                            Denmark arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Chr. Hansen

                            Denmark arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Probiotic

                            Therapeutic Area : Pharmacology/Toxicology

                            Study Phase : Phase II

                            Sponsor : Atlantia Food Clinical Trials

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            The Effect of a Probiotic Strain on Aspirin-induced GI Damage.

                            Details : This is a Probiotic drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Aspirin Side Effects.

                            Product Name : Undisclosed

                            Product Type : Probiotic

                            Upfront Cash : Inapplicable

                            July 25, 2017

                            Lead Product(s) : Probiotic

                            Therapeutic Area : Pharmacology/Toxicology

                            Highest Development Status : Phase II

                            Sponsor : Atlantia Food Clinical Trials

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            EmeraMed

                            Ireland arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            EmeraMed

                            Ireland arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Emeramide

                            Therapeutic Area : Pharmacology/Toxicology

                            Study Phase : Phase II

                            Sponsor : NBMI Science AB

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Pilot Proof of Concept Study of NBMI Treatment of Mercury Intoxication

                            Details : Emeramide is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Mercury Poisoning.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            July 01, 2015

                            Lead Product(s) : Emeramide

                            Therapeutic Area : Pharmacology/Toxicology

                            Highest Development Status : Phase II

                            Sponsor : NBMI Science AB

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth